Cubist Pharmaceuticals, Inc.

Cubist receives CUBICIN Paragraph IV notice letter

Cubist Receives CUBICIN Paragraph IV Notice Letter

New Dimensions to Cubist Pharmaceuticals

The Little Guys Are Pharma’s New Stars

Needham & Company Maintains a 'Hold' on Cubist Pharmaceuticals (CBST); 4Q11 Review. U.S. Cubicin Sales Guidance for 2012 In-line with Our Expectations

Cubist Pharmaceuticals Reports 2011 Fourth Quarter and Full Year Financial Results

Cubist reports Q4 EPS 66c vs. consensus 32c

Cubist Pharmaceuticals, Inc. (CBST) Posts Q4 EPS of 66c

Cubist Pharmaceuticals Reports 2011 Fourth Quarter and Full Year Financial Results

Cubist announces executive changes

5 Stocks Set to Soar on Bullish Earnings

Cubist Pharmaceuticals: Earnings Preview

Cramer's 'Mad Money' Recap: Maintaining Market Discipline (Final)

'Mad Money Lightning Round': Biogen Shines

Cubist, Hydra announce plans to begin phase 1 trial for Novel TRPA1

Cubist Pharmaceuticals and Hydra Biosciences Announce Plans to Begin Phase 1 Clinical Trial for Novel TRPA1 Modulator to Treat Acute Pain

24/7 Wall St. Closing Bell (COST, XOM, AKAM, P, SCCO, MRK, AYI, CBST, AA, INHX, PSOF, IDIX, NFLX, THRX, LTRX)

Cubist Announces Full Year 2011 Total CUBICIN Net Product Revenues of $735.5 Million, Up 18% Over 2010

Cubist reports FY11 CUBICIN net product revenues $735.5M

Cubist Pharmaceuticals and The New England Patriots Radio Network Honor Merrimack, New Hampshire, Science Teacher

Cubist Pharmaceuticals and The New England Patriots Radio Network Honor Merrimack, New Hampshire, Science Teacher

Cubist Pharmaceuticals and The New England Patriots Radio Network Honor Merrimack, New Hampshire, Science Teacher

Tracking Dividends in Biotech: Who Follows Amgen in Payouts? (AMGN, PFE, MRK, BIIB, CELG, ALXN, CBST, PDLI, REGN, VRTX)

4 Heavily Shorted Stocks That Could Climb Higher (AVB, BXP, UTHR, CBST)

Cubist Pharmaceuticals Inc. (CBST) EVP, COO Robert J Perez sells 25,000 Shares

The 2 Best-Performing Sectors Over the Last Decade

5 Pharmaceutical Stocks to Buy, 1 to Avoid

iMarc Receives Three International Davey Awards

Cubist announces first patient dosed in Phase 3 CXA-201 trial

Cubist Announces First Patient Dosed in Pivotal Global Phase 3 Trial of CXA-201 for Complicated Intra-Abdominal Infections

Cubist Pharmaceuticals completes deal for Adolor

Cubist Pharmaceuticals completes deal for Adolor

Cubist entered contingent payment rights agreement

Is Pharmacyclics the Perfect Stock?

Cubist announces completion of Adolor acquisition

Cubist Pharmaceuticals Completes Acquisition of Adolor Corporation

Cubist takeover of Adolor progresses as stock is tendered

Cubist Pharmaceuticals, Inc. Reports Acquisition of 75 Percent of Adolor Corporation Stock in Initial Tender Offer

Cubist announces results of initial tender offer for outstanding share of Adolor

Cubist Pharmaceuticals Announces Results of Initial Tender Offer for Outstanding Shares of Adolor Corporation and Commencement of Subsequent Offering Period